生物股份(600201) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue fell by 40.06% to CNY 334,053,615.39 year-on-year[11] - Net profit attributable to shareholders decreased by 46.46% to CNY 158,648,281.45 compared to the same period last year[11] - Basic earnings per share dropped by 48.15% to CNY 0.14 compared to the previous year[11] - The company experienced a significant decline in both revenue and profit, indicating challenges in the current market environment[11] - Total revenue for Q1 2019 was 334,053,615.39 RMB, a decrease of 40% compared to 557,328,263.99 RMB in Q1 2018[72] - Operating profit for Q1 2019 was 186,289,255.48 RMB, compared to 350,312,066.39 RMB in Q1 2018, indicating a decline of about 47%[72] - Operating revenue for the first quarter of 2019 was CNY 4,513,635.73, down 33.73% from CNY 6,812,176.72 in the first quarter of 2018[77] - The company's operating profit for the first quarter of 2019 was CNY 11,282,540.80, slightly higher than CNY 10,832,848.23 in the first quarter of 2018, indicating a growth of about 4.13%[79] Cash Flow and Liquidity - Net cash flow from operating activities was negative at CNY -71,251,366.82, a decrease of 221.72% year-on-year[11] - Cash received from operating activities decreased by 27.25 million yuan, down 57.06%, mainly due to reduced bank interest income[25] - Cash flow from operating activities showed a net outflow of ¥71,251,366.82, compared to a net inflow of ¥58,538,667.06 in the previous period, indicating a significant decline in operational cash generation[84] - The total cash and cash equivalents at the end of the period stood at ¥801,455,778.57, down from ¥2,205,726,854.32 at the end of the previous period, indicating a significant reduction in liquidity[86] - The net cash increase for the period was -¥213,063,490.34, compared to -¥246,032,788.67 in the previous period, showing a slight improvement in cash flow management[86] Assets and Liabilities - Total assets decreased by 1.60% to CNY 6,212,152,542.06 compared to the end of the previous year[11] - Total liabilities decreased from 1.09 billion yuan to 896.43 million yuan, a decrease of 17.66%[47] - Total assets as of March 31, 2019, were 4,822,646,936.95 RMB, a decrease from 4,974,795,813.18 RMB at the end of 2018[68] - Total liabilities as of March 31, 2019, were 878,353,363.22 RMB, down from 974,790,533.22 RMB at the end of 2018, showing a reduction of approximately 10%[68] - The total assets amount to $4,974,795,813.18, with non-current assets totaling $2,745,386,005.32[101] - The company’s total liabilities stand at $974,790,533.22, indicating a stable financial position[103] Shareholder Information - The total number of shareholders at the end of the reporting period was 35,311[17] - The largest shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., held 10.55% of the shares[17] Expenses and Costs - Operating costs decreased by 4.03 million yuan, down 30.27%, corresponding to the reduction in biopharmaceutical industry revenue[23] - Management expenses decreased by 22.70 million yuan, down 55.45%, mainly due to high stock incentive costs in the previous period[24] - Cash paid for purchasing goods and services increased by 43.84 million yuan, up 41.72%, mainly due to increased material payments in the biopharmaceutical industry[25] - Cash paid for fixed assets and other long-term assets decreased by 31.90 million yuan, down 30.15%, mainly due to reduced payments for projects and equipment in the Jin Yu Industrial Park[25] Government Subsidies and Other Income - The company reported a government subsidy of CNY 3,412,915.63 related to normal business operations[11] - The company's investment income for the first quarter of 2019 was CNY 9,297,670.98, an increase from CNY 5,302,865.32 in the first quarter of 2018, reflecting a growth of approximately 75.80%[77]